Cargando…

An in vivo rabbit joint injury model to measure trauma-induced coagulopathy and the effect of timing of administration of ketotifen fumarate on posttraumatic joint contracture

OBJECTIVES: Using a rabbit in vivo joint injury model, the primary objective of the study was to determine if a relationship exists between earlier time to initiation of ketotifen fumarate (KF) treatment and posttraumatic joint contracture (PTJC) reduction. The secondary objective was to determine i...

Descripción completa

Detalles Bibliográficos
Autores principales: You, Daniel, Maarouf, Nadia, Hildebrand, Kevin, Soo, Andrea, Schneider, Prism
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900463/
https://www.ncbi.nlm.nih.gov/pubmed/35282394
http://dx.doi.org/10.1097/OI9.0000000000000177
_version_ 1784664120338939904
author You, Daniel
Maarouf, Nadia
Hildebrand, Kevin
Soo, Andrea
Schneider, Prism
author_facet You, Daniel
Maarouf, Nadia
Hildebrand, Kevin
Soo, Andrea
Schneider, Prism
author_sort You, Daniel
collection PubMed
description OBJECTIVES: Using a rabbit in vivo joint injury model, the primary objective of the study was to determine if a relationship exists between earlier time to initiation of ketotifen fumarate (KF) treatment and posttraumatic joint contracture (PTJC) reduction. The secondary objective was to determine if a coagulation response could be detected with serial thrombelastography (TEG) analysis following acute trauma in this model. METHODS: PTJC of the knee were created in 25 skeletally mature, New Zealand White rabbits. Five groups of 5 animals were studied: a control group that received twice daily subcutaneous injections of normal saline and 4 treatment groups that received twice daily subcutaneous injections of KF (0.5 mg/kg) starting immediately, 1-, 2-, and 4-weeks post-injury. After 8 weeks of immobilization, flexion contractures were measured biomechanically. Serial TEG analysis was performed on the control group animals pre-injury and weekly post-injury. RESULTS: The average joint contracture in the Control Group (43.1° ± 16.2°) was higher than all KF treatment groups; however, the differences were not statistically significant. The average joint contracture was lowest in the 2-week post-injury treatment group (29.4° ± 12.1°), although not statistically significant compared to the other treatment groups. Serial TEG analysis demonstrated significantly higher mean maximal amplitude (maximal amplitude = 68.9 ± 1.7 mm; P < .001), alpha-angle (81.9° ± 0.9°; P < .001), and coagulation index (4.5 ± 0.3; P < .001) 1-week post-injury, which normalized to pre-injury values by 5-weeks post-injury. CONCLUSIONS: The use of the mast cell stabilizer KF within 2 weeks of injury demonstrated a nonsignificant trend towards reducing joint contracture in a rabbit in vivo model of PTJC. TEG and the in vivo rabbit joint injury model may be valuable in future preclinical studies of venous thromboembolism prevention and furthering our understanding of the pathophysiology of posttraumatic hypercoagulability.
format Online
Article
Text
id pubmed-8900463
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-89004632022-03-10 An in vivo rabbit joint injury model to measure trauma-induced coagulopathy and the effect of timing of administration of ketotifen fumarate on posttraumatic joint contracture You, Daniel Maarouf, Nadia Hildebrand, Kevin Soo, Andrea Schneider, Prism OTA Int Clinical/Basic Science Research Article OBJECTIVES: Using a rabbit in vivo joint injury model, the primary objective of the study was to determine if a relationship exists between earlier time to initiation of ketotifen fumarate (KF) treatment and posttraumatic joint contracture (PTJC) reduction. The secondary objective was to determine if a coagulation response could be detected with serial thrombelastography (TEG) analysis following acute trauma in this model. METHODS: PTJC of the knee were created in 25 skeletally mature, New Zealand White rabbits. Five groups of 5 animals were studied: a control group that received twice daily subcutaneous injections of normal saline and 4 treatment groups that received twice daily subcutaneous injections of KF (0.5 mg/kg) starting immediately, 1-, 2-, and 4-weeks post-injury. After 8 weeks of immobilization, flexion contractures were measured biomechanically. Serial TEG analysis was performed on the control group animals pre-injury and weekly post-injury. RESULTS: The average joint contracture in the Control Group (43.1° ± 16.2°) was higher than all KF treatment groups; however, the differences were not statistically significant. The average joint contracture was lowest in the 2-week post-injury treatment group (29.4° ± 12.1°), although not statistically significant compared to the other treatment groups. Serial TEG analysis demonstrated significantly higher mean maximal amplitude (maximal amplitude = 68.9 ± 1.7 mm; P < .001), alpha-angle (81.9° ± 0.9°; P < .001), and coagulation index (4.5 ± 0.3; P < .001) 1-week post-injury, which normalized to pre-injury values by 5-weeks post-injury. CONCLUSIONS: The use of the mast cell stabilizer KF within 2 weeks of injury demonstrated a nonsignificant trend towards reducing joint contracture in a rabbit in vivo model of PTJC. TEG and the in vivo rabbit joint injury model may be valuable in future preclinical studies of venous thromboembolism prevention and furthering our understanding of the pathophysiology of posttraumatic hypercoagulability. Lippincott Williams & Wilkins 2022-03-10 /pmc/articles/PMC8900463/ /pubmed/35282394 http://dx.doi.org/10.1097/OI9.0000000000000177 Text en Copyright © 2022 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Orthopaedic Trauma Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Clinical/Basic Science Research Article
You, Daniel
Maarouf, Nadia
Hildebrand, Kevin
Soo, Andrea
Schneider, Prism
An in vivo rabbit joint injury model to measure trauma-induced coagulopathy and the effect of timing of administration of ketotifen fumarate on posttraumatic joint contracture
title An in vivo rabbit joint injury model to measure trauma-induced coagulopathy and the effect of timing of administration of ketotifen fumarate on posttraumatic joint contracture
title_full An in vivo rabbit joint injury model to measure trauma-induced coagulopathy and the effect of timing of administration of ketotifen fumarate on posttraumatic joint contracture
title_fullStr An in vivo rabbit joint injury model to measure trauma-induced coagulopathy and the effect of timing of administration of ketotifen fumarate on posttraumatic joint contracture
title_full_unstemmed An in vivo rabbit joint injury model to measure trauma-induced coagulopathy and the effect of timing of administration of ketotifen fumarate on posttraumatic joint contracture
title_short An in vivo rabbit joint injury model to measure trauma-induced coagulopathy and the effect of timing of administration of ketotifen fumarate on posttraumatic joint contracture
title_sort in vivo rabbit joint injury model to measure trauma-induced coagulopathy and the effect of timing of administration of ketotifen fumarate on posttraumatic joint contracture
topic Clinical/Basic Science Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900463/
https://www.ncbi.nlm.nih.gov/pubmed/35282394
http://dx.doi.org/10.1097/OI9.0000000000000177
work_keys_str_mv AT youdaniel aninvivorabbitjointinjurymodeltomeasuretraumainducedcoagulopathyandtheeffectoftimingofadministrationofketotifenfumarateonposttraumaticjointcontracture
AT maaroufnadia aninvivorabbitjointinjurymodeltomeasuretraumainducedcoagulopathyandtheeffectoftimingofadministrationofketotifenfumarateonposttraumaticjointcontracture
AT hildebrandkevin aninvivorabbitjointinjurymodeltomeasuretraumainducedcoagulopathyandtheeffectoftimingofadministrationofketotifenfumarateonposttraumaticjointcontracture
AT sooandrea aninvivorabbitjointinjurymodeltomeasuretraumainducedcoagulopathyandtheeffectoftimingofadministrationofketotifenfumarateonposttraumaticjointcontracture
AT schneiderprism aninvivorabbitjointinjurymodeltomeasuretraumainducedcoagulopathyandtheeffectoftimingofadministrationofketotifenfumarateonposttraumaticjointcontracture
AT youdaniel invivorabbitjointinjurymodeltomeasuretraumainducedcoagulopathyandtheeffectoftimingofadministrationofketotifenfumarateonposttraumaticjointcontracture
AT maaroufnadia invivorabbitjointinjurymodeltomeasuretraumainducedcoagulopathyandtheeffectoftimingofadministrationofketotifenfumarateonposttraumaticjointcontracture
AT hildebrandkevin invivorabbitjointinjurymodeltomeasuretraumainducedcoagulopathyandtheeffectoftimingofadministrationofketotifenfumarateonposttraumaticjointcontracture
AT sooandrea invivorabbitjointinjurymodeltomeasuretraumainducedcoagulopathyandtheeffectoftimingofadministrationofketotifenfumarateonposttraumaticjointcontracture
AT schneiderprism invivorabbitjointinjurymodeltomeasuretraumainducedcoagulopathyandtheeffectoftimingofadministrationofketotifenfumarateonposttraumaticjointcontracture